Business Description
Kiora Pharmaceuticals Inc
NAICS : 325413
SIC : 2835
ISIN : US30233M1071
Description
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 403.26 | |||||
| Equity-to-Asset | 0.78 | |||||
| Debt-to-EBITDA | 0.03 | |||||
| Interest Coverage | 507.92 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | -2.49 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 64.7 | |||||
| 3-Year EPS without NRI Growth Rate | 68.9 | |||||
| 3-Year FCF Growth Rate | 68.4 | |||||
| 3-Year Book Growth Rate | -77.5 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 14-Day RSI | 40.32 | |||||
| 12-1 Month Momentum % | -15.11 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 8.97 | |||||
| Quick Ratio | 8.97 | |||||
| Cash Ratio | 8.23 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -281.4 | |||||
| Shareholder Yield % | -127.15 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | 38.09 | |||||
| Net Margin % | 34.68 | |||||
| FCF Margin % | 51.15 | |||||
| ROE % | 24.72 | |||||
| ROA % | 18.33 | |||||
| ROIC % | 64.86 | |||||
| ROC (Joel Greenblatt) % | 2118.75 | |||||
| ROCE % | 8.42 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 3.03 | |||||
| Price-to-Owner-Earnings | 2.45 | |||||
| PS Ratio | 0.91 | |||||
| PB Ratio | 0.37 | |||||
| Price-to-Tangible-Book | 0.48 | |||||
| EV-to-EBIT | -7.51 | |||||
| EV-to-EBITDA | -7.45 | |||||
| EV-to-Revenue | -1.11 | |||||
| EV-to-Forward-Revenue | 0.66 | |||||
| EV-to-FCF | -2.16 | |||||
| Price-to-Net-Current-Asset-Value | 0.48 | |||||
| Price-to-Net-Cash | 0.54 | |||||
| Earnings Yield (Greenblatt) % | -13.31 | |||||
| FCF Yield % | 73.41 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Kiora Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 14.72 | ||
| EPS (TTM) (€) | -4.445 | ||
| Beta | -0.97 | ||
| Volatility % | 26.04 | ||
| 14-Day RSI | 40.32 | ||
| 14-Day ATR (€) | 0.000007 | ||
| 20-Day SMA (€) | 3.7665 | ||
| 12-1 Month Momentum % | -15.11 | ||
| 52-Week Range (€) | 3.429 - 7.029 | ||
| Shares Outstanding (Mil) | 3 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Kiora Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Kiora Pharmaceuticals Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Kiora Pharmaceuticals Inc Frequently Asked Questions
What is Kiora Pharmaceuticals Inc(STU:7EY)'s stock price today?
The current price of STU:7EY is €3.77. The 52 week high of STU:7EY is €7.03 and 52 week low is €3.43.
When is next earnings date of Kiora Pharmaceuticals Inc(STU:7EY)?
The next earnings date of Kiora Pharmaceuticals Inc(STU:7EY) is .
Does Kiora Pharmaceuticals Inc(STU:7EY) pay dividends? If so, how much?
Kiora Pharmaceuticals Inc(STU:7EY) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers